Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Eye Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Eye Neoplasm

Cancer Family

Eye Neoplasm

CI-CAN-00000017Explore in graph →

Non-malignant86 active trials2 approved drugs19 evidence items

NCIt: C3030
MeSH: D005134

Overview
Statistics
Survival
Genomics7
Variants & evidence19
Drugs12
Trials463
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (16)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–16 of 16 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Prognostic parameters in uveal melanoma and their association with BAP1 expression.
· Br J Ophthalmol · 2014 · PMID 25147369 · validated civic_curation pubmed
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
· JAMA · 2014 · PMID 24938562 · validated civic_curation pubmed
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
· Br J Cancer · 2017 · PMID 28103611 · validated civic_curation pubmed
Polymorphisms of CDKN1A gene and risk of retinoblastoma.
· Carcinogenesis · 2013 · PMID 24045412 · validated civic_curation pubmed
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
· Lancet Oncol · 2012 · PMID 22805292 · validated civic_curation pubmed
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.
· Nat Genet · 2013 · PMID 23793026 · validated civic_curation pubmed
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
· Clin Cancer Res · 2013 · PMID 23434733 · validated civic_curation pubmed

Showing 1–16 of 16 publications

Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.

· Mol Cancer Ther · 2014 · PMID 24899684 · validated civic_curation pubmed

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.

· Oncogene · 2014 · PMID 24141786 · validated civic_curation pubmed

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.

· Clin Cancer Res · 2012 · PMID 22038994 · validated civic_curation pubmed

Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.

· Cancer Res · 2015 · PMID 25952648 · validated civic_curation pubmed

BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.

· Oncotarget · 2015 · PMID 26397223 · validated civic_curation pubmed

Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.

· Mol Cancer Ther · 2013 · PMID 24140933 · validated civic_curation pubmed

Kothari et al. Cancer Med 2020

· 2020 · PMID 32633890 · validated cbioportal_study pubmed

Francis et al. Cancers 2021

· 2021 · PMID 33466343 · validated cbioportal_study pubmed

Johansson et al. Oncotarget 2016

· 2016 · PMID 26683228 · validated cbioportal_study pubmed